Sclerosol

(Talc)

ApprovedSmall molecule

SSciarra

Sclerosol is one of 8 small molecule programs targeting Pleural effusion. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Pleural EffusionActive, not recruiting

PneumothoraxNot yet recruiting

Pleural EffusionApproved

Active, not recruiting

PneumothoraxPreclinical

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Pleural Effusion

#DrugCompanyPhaseTrials

Sclerosol

SSciarra

Approved

3 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Interleukin-2 (IL2)

Astellas

Phase 1

1 4

JMKX000197

JJemincare

Phase 1

2 5

Intrapleural Medications

SSwedish Medical Center

Preclinical

1 6

Recombinant Human Interleukin-2

SSecond Xiangya Hospital of Central South University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalNot yet recruiting

Pneumothorax

NCT06883188

Clinical

Trials by Indication[1]

Pleural effusion3 trials

Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion

Terminated·—·Phase 4·NCT04792970·4 enrolled

Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion

Completed·—·Phase 3·NCT02674243·60 enrolled

Talc in Treating Patients With Malignant Pleural Effusion

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00002622·501 enrolled

Pneumothorax1 trial

A Pilot Randomised Study Comparing the Clinical Efficacy of Stopping Air Leak by Talc Pleurodesis or Autologous Blood Patch Therapy in Secondary Spontaneous Pneumothorax

Not yet recruiting·CChinese University of Hong Kong·Preclinical·NCT06883188·30 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 24, 1997

SCLEROSOL

NDA NDA020587

Dec 15, 2003

TALC

NDA NDA021388

May 1, 2017

STERITALC

NDA NDA205555

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Talc. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Talc compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Talc. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA205555). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Sciarra company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSciarra

Sclerosol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Pleural effusion3 trials

Pneumothorax1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News